Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
1.
Int J Obes (Lond) ; 46(12): 2163-2167, 2022 12.
Artículo en Inglés | MEDLINE | ID: mdl-36008680

RESUMEN

Despite its cardiometabolic benefits, bariatric surgery has historically been underused in patients with obesity and diabetes, but contemporary data are lacking. Among 1,520,182 patients evaluated from 2013 to 2019 within a multicenter, longitudinal, US registry of outpatients with diabetes, we found that 462,033 (30%) met eligibility for bariatric surgery. After a median follow-up of 854 days, 6310/384,859 patients (1.6%) underwent primary bariatric surgery, with a slight increase over time (0.38% per year [2013] to 0.68% per year [2018]). Patients who underwent bariatric surgery were more likely to be female (63% vs. 56%), white (87% vs. 82%), have higher body mass indices (42.1 ± 6.9 vs. 40.6 ± 5.9 kg/m2), and depression (23% vs. 14%; p < 0.001 for all). Over a median (IQR) follow-up after surgery of 722 days (364-993), patients who underwent bariatric surgery had lost an average of 11.8 ± 18.5 kg (23% of excess body weight), 10.2% were on fewer glucose-lowering medications, and 8.4% were on fewer antihypertensives. Despite bariatric surgery being safer and more accessible over the past two decades, less than one in fifty eligible patients with diabetes receive this therapy.


Asunto(s)
Cirugía Bariátrica , Diabetes Mellitus Tipo 2 , Diabetes Mellitus , Obesidad Mórbida , Humanos , Femenino , Masculino , Pérdida de Peso , Cirugía Bariátrica/efectos adversos , Obesidad/complicaciones , Obesidad/epidemiología , Obesidad/cirugía , Sistema de Registros , Diabetes Mellitus Tipo 2/complicaciones , Diabetes Mellitus Tipo 2/epidemiología , Diabetes Mellitus Tipo 2/cirugía , Obesidad Mórbida/complicaciones , Obesidad Mórbida/epidemiología , Obesidad Mórbida/cirugía , Estudios Retrospectivos
2.
Curr Cardiol Rep ; 23(7): 91, 2021 06 14.
Artículo en Inglés | MEDLINE | ID: mdl-34121150

RESUMEN

PURPOSE OF REVIEW: As medicine strives to become more patient-centered, patient-reported outcomes (PROs) are often used to describe patients' symptoms, function, and quality of life. This review describes the key concepts of PROs specific to heart failure in clinical trials and their potential role in clinical practice. RECENT FINDINGS: As the Food and Drug Administration has increasingly emphasized how it values PROs as clinical outcome assessments, including its recent qualification of the Kansas City Cardiomyopathy Questionnaire (KCCQ), clinical trials have increasingly used them to evaluate novel therapies. This has been enhanced by an increasing understanding of how to interpret KCCQ scores. Its use in clinical practice, including the importance of providers sharing results with their patients, is just emerging. PROs provide unique insights into the benefits of treatment from patients' perspectives and while their role in clinical care is just beginning, they offer an important opportunity to improve the patient-centeredness of care.


Asunto(s)
Cardiomiopatías , Insuficiencia Cardíaca , Estado de Salud , Insuficiencia Cardíaca/tratamiento farmacológico , Humanos , Medición de Resultados Informados por el Paciente , Calidad de Vida , Encuestas y Cuestionarios
3.
Curr Probl Cardiol ; 48(8): 101231, 2023 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-35500735

RESUMEN

Obesity has become a worldwide public health issue. Many obese patients concomitantly suffer with heart failure with reduced ejection fraction. There have been reports of improvement in left ventricular systolic function following significant weight loss after bariatric surgery. We sought to investigate this phenomenon within our institution. This was a retrospective single-center analysis of patients conducted between 2010 and 2019. The study included patients with morbid obesity (body mass index >35 kg/m2 and an obesity-related comorbid condition, or a body mass index >40 kg/m2) and left ventricular systolic dysfunction. Analysis was performed based on systolic function recovery after bariatric surgery and advanced heart failure therapy. Of the 190 patients identified, 57 patients had a left ventricular ejection fraction of <40%. Twenty-two patients underwent bariatric surgery, of which at least 54.5% had systolic function recovery. Patients who had systolic function recovery after bariatric surgery were significantly older (51.58 years ± 10.48 vs 32.3 years ± 5.03, P = 0.001). Older age and female sex were predictors of systolic function recovery. In patients with obesity and heart failure with reduced ejection fraction, weight loss following bariatric surgery was shown to be correlated with significant improvement in left ventricular systolic function.


Asunto(s)
Cirugía Bariátrica , Insuficiencia Cardíaca , Obesidad Mórbida , Disfunción Ventricular Izquierda , Humanos , Femenino , Función Ventricular Izquierda , Volumen Sistólico , Estudios Retrospectivos , Insuficiencia Cardíaca/complicaciones , Insuficiencia Cardíaca/cirugía , Cirugía Bariátrica/efectos adversos , Disfunción Ventricular Izquierda/complicaciones , Obesidad Mórbida/complicaciones , Obesidad Mórbida/cirugía , Pérdida de Peso
4.
Int J Artif Organs ; 45(4): 404-411, 2022 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-34702105

RESUMEN

BACKGROUND: The Model for End-Stage Liver Disease (MELD) score was originally described as a marker of survival in chronic liver disease. More recently, MELD and its derivatives, MELD excluding INR (MELD-XI) and MELD with sodium (MELD-Na), have been applied more broadly as outcome predictors in heart transplant, left ventricular assist device placement, heart failure, and cardiogenic shock, with additional promising data to support the use of these scores for prediction of survival in those undergoing veno-arterial extracorporeal membrane oxygenation (VA ECMO). METHODS: This study assessed the prognostic impact of MELD in patients with cardiogenic shock undergoing VA ECMO via a single-center retrospective review from January 2014 to March 2020. MELD, MELD-XI, and MELD-Na scores were calculated using laboratory values collected within 48 h of VA ECMO initiation. Multivariate Cox regression analyses determined the association between MELD scores and the primary outcome of 90-day mortality. Receiver operating characteristics (ROC) were used to estimate the discriminatory power for MELD in comparison with previously validated SAVE score. RESULTS: Of the 194 patients, median MELD was 20.1 (13.7-26.2), and 90-day mortality was 62.1%. There was a significant association between MELD score and mortality up to 90 days (hazard ratio (HR) = 1.945, 95% confidence interval (95% CI) = 1.244-3.041, p = 0.004) after adjustment for age, indication for VA ECMO, and sex. The prognostic significance of MELD score for 90-day mortality revealed an AUC of 0.645 (95% CI = 0.565-0.725, p < 0.001). MELD-Na score and MELD-XI score were not associated with mortality. CONCLUSION: MELD score accurately predicts long-term mortality and may be utilized as a valuable decision-making tool in patients undergoing VA ECMO.


Asunto(s)
Enfermedad Hepática en Estado Terminal , Oxigenación por Membrana Extracorpórea , Enfermedad Hepática en Estado Terminal/diagnóstico , Enfermedad Hepática en Estado Terminal/terapia , Mortalidad Hospitalaria , Humanos , Estudios Retrospectivos , Índice de Severidad de la Enfermedad , Choque Cardiogénico/diagnóstico , Choque Cardiogénico/terapia
5.
Methodist Debakey Cardiovasc J ; 17(1): e1-e9, 2021 Apr 05.
Artículo en Inglés | MEDLINE | ID: mdl-34104328

RESUMEN

Patient-reported outcomes (PROs) are elicited directly from patients so they can describe their overall health status, including their symptoms, function, and quality of life. While commonly used as end points in clinical trials, PROs can play an important role in routine clinical care, population health management, and as a means for quantifying the quality of patient care. In this review, we propose that PROs be used to improve patient-centered care in the treatment of cardiovascular diseases given their importance to patients and society and their ability to improve doctor- provider communication. Furthermore, given the current variability in patients' health status across different clinics and the fact that PROs can be improved by titrating therapy, we contend that PROs have a key opportunity to serve as measures of healthcare quality.


Asunto(s)
Enfermedades Cardiovasculares/terapia , Evaluación de Procesos y Resultados en Atención de Salud/normas , Medición de Resultados Informados por el Paciente , Atención Dirigida al Paciente/normas , Mejoramiento de la Calidad/normas , Indicadores de Calidad de la Atención de Salud/normas , Enfermedades Cardiovasculares/diagnóstico , Enfermedades Cardiovasculares/economía , Análisis Costo-Beneficio , Estado Funcional , Costos de la Atención en Salud , Humanos , Evaluación de Procesos y Resultados en Atención de Salud/economía , Atención Dirigida al Paciente/economía , Psicometría , Mejoramiento de la Calidad/economía , Indicadores de Calidad de la Atención de Salud/economía , Calidad de Vida , Resultado del Tratamiento
6.
Cureus ; 13(2): e13319, 2021 Feb 12.
Artículo en Inglés | MEDLINE | ID: mdl-33747642

RESUMEN

Most cases of non-bacterial thrombotic endocarditis (NBTE) tend to be related to malignancy or rheumatologic and autoimmune disorders like systemic lupus erythematosus. Rheumatoid arthritis (RA) itself has been associated with increased atherosclerosis, coronary artery plaque formation, and endothelial damage. However, it is rare to see NBTE in RA, simultaneously presenting with the acute coronary syndrome and acute limb ischemia due to distant embolization. Here we present a case of a 46-year-old female presenting with chest pain and right leg numbness, found to have ST-elevation myocardial infarction (STEMI) and occlusion of a peripheral artery due to embolization of vegetation present in the aortic valve. We also provide an extensive literature review of the relationship between NBTE and MI. One must be extra vigilant in managing these patients, especially if the size of vegetation is large as it has a tendency to embolize causing devastating complications.

7.
JACC Case Rep ; 3(7): 1013-1017, 2021 Jul 07.
Artículo en Inglés | MEDLINE | ID: mdl-34317675

RESUMEN

Left ventricular assist devices (LVADs) are surgically implanted mechanical devices indicated for patients with advanced heart failure and are known to come with several complications. Here we present a case series, and review 1 documented report, of LVAD vasculitis, a presumed new LVAD immune/humoral related phenomenon. (Level of Difficulty: Advanced.).

SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA